PRELIMINARY EVALUATION OF SERIAL 18FDG‐PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER

摘要: Palladia(TM) (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI) approved for treatment of canine mast cell tumors. Receptor dysregulation leads to tumor growth, progression, and metastasis. Toceranib's targets include vascular endothelial growth factor (VEGFR-2/Flk-1/KDR), platelet-derived receptor, kit. Positron Emission Tomography/Computed Tomography (PET/CT) used commonly diagnose, prognosticate, monitor response antineoplastic therapy in human patients. In this study, serial PET/CT imaging with (18) F-fluorodeoxyglucose ((18) FDG) was assess toceranib dogs measurable solid malignancies. Six tumor-bearing underwent assessment using both standard RECIST criteria prior at median 5 weeks postinitiation treatment. Toceranib prescribed initially target dose 3.25 mg/kg PO q48 h, subsequent modifications based on observed toxicity. Treatment continued patients achieving stable disease acceptable drug tolerance. One dog maintained despite modification due toxicity; clinical image-based responses were seen after 10 therapy. All others had or progressive restaging first recheck. . Due discordance anatomic metabolic imaging, further studies are needed investigate the role molecular identify other potential toceranib.